“Graves眼病” 越治越重!主治医生该何去何从?

2019-10-09 美娜 医学界内分泌频道

患者41岁男性,于1年前无明显诱因出现多汗、手抖等不适,未诊治。于4个月前患者出现双眼突出、胀痛、结膜充血、复视、视力下降等不适症状,就诊于我科门诊,诊断为“甲亢(Graves病)”,予以患者甲巯咪唑30mgqd,患者一直规律服用药物,症状有所缓解,期间在外院服中药治疗,用药后患者突眼症状加重,于2019年7月复诊,调整甲巯咪唑15mgqd,症状加重。

病史特点

患者41岁男性,于1年前无明显诱因出现多汗、手抖等不适,未诊治。于4个月前患者出现双眼突出、胀痛、结膜充血、复视、视力下降等不适症状,就诊于我科门诊,诊断为“甲亢(Graves病)”,予以患者甲巯咪唑30mgqd,患者一直规律服用药物,症状有所缓解,期间在外院服中药治疗,用药后患者突眼症状加重,于2019年7月复诊,调整甲巯咪唑15mgqd,症状加重。

既往史:无高血压、冠心病、糖尿病等相关疾病。

吸烟20余年、平均10支/日,未戒烟,饮酒史20余年、间断饮酒

查体:血压120/86mmHg,皮肤潮湿,未见黄疸,甲状腺Ⅱ度肿大,无压痛,未触及震颤,未闻及血管杂音。双手平举可见细颤,手心有汗。双目炯炯有神,眼球向前突出,左眼突眼度23mm,右眼突眼度22mm;上眼睑挛缩、睑裂宽,双眼不完全闭合;Stellwag征(+);von Graefe征(+);Joffroy征(-);Mobius征(+)。双下肢无水肿。

入院前的甲功变化



入院后相关检查结果

▎甲功:



▎甲状腺B超

甲状腺体积增大并弥漫性病变。
甲状腺ECT检查:双叶甲状腺弥漫性肿大,符合甲亢。
甲状腺摄碘率检查:甲状腺摄碘率高于正常范围提示甲亢。

▎眼眶CT

双侧眼球突出,双侧上、下直肌及左侧内直肌明显增粗,符合甲状腺相关性眼病;
双侧上颌窦及筛窦炎症。

由上述病史及检查结果,诊断明确“1.Graves病 2.Graves病眼病”。但为什么症状越来越重?该怎么治疗?

首先了解一下“Graves病眼病”

Graves病眼病是免疫功能紊乱所致的,与甲状腺疾病相关的眼病,其发病机制尚未完全清楚,严重者可以影响视力并致盲[1,2]。临床上多表现为单侧或双侧眼球突出,且在年轻女性甲状腺功能亢进 (简称甲亢) 患者中高发,但病情严重者更容易见于男性或50岁以上人群,原因尚不清楚。

Graves病眼病主要病理改变是眼眶软组织和眼外肌的炎症反应。早期淋巴细胞和浆细胞在眼外肌结缔组织中浸润,眼外肌肌内膜的成纤维细胞活化后可分泌氨基葡聚糖 (GAGs) 和胶原,GAGs结合水分后造成组织水肿,成为眼球后组织肿胀的主要原因。在疾病慢性阶段,受累的眼外肌胶原沉积,引起成纤维细胞增殖,纤维增生和脂肪沉积。其基因易感性、关键因子的改变等研究均有不同进展。 

▎Graves病眼病主要临床表现:

广泛累及眼眶软组织(眼外肌、脂肪、泪腺)
表现为突眼、眼睑退缩、球结膜水肿,眶周水肿和眼球运动障碍等
严重时会导致暴露性角膜炎、复视、及视神经受压等
居致盲性眼眶疾病之首

Graves病眼病的严重程度评估(即EUGOGO评估标准)及眼部病变的临床活动性评分(即CAS评分)对其治疗起决定性作用。



▎Graves病眼病活动度的评估:

自发性眼球后疼痛感 
眼球运动时伴有疼痛
眼睑充血
眼睑水肿
球结膜充血
球结膜水肿
眼阜水肿

以上各点各1分,共7分, CAS评分 ≧3 为活动性。积分越高,活动度越高。

患者入院前,为控制患者甲亢予以甲巯咪唑30mgqd,但为什么患者症状越来越重了呢?

▎我们考虑以下几点可能导致了这样的结局:

吸烟是Graves病眼病最重要的一个危险因素,既往有研究发现,吸烟者Graves病眼病发病风险是非吸烟者的1.3倍,突眼风险是2.6倍,复视风险是3.1倍,而这个患者整个病程中未戒烟,这会影响治疗效果。

由于甲亢及甲减均会对Graves病眼病造成不利影响,因此,及时纠正甲状腺功能异常并维持其稳定是极为必要的。由该患者病史可知,患者的甲功一直处于不平稳状态,Graves病眼病的患者抗甲状腺药物治疗时需密切观察甲功,患者入院时已出现药物性甲减,该患者未定期复诊。

该患者病程中,外院服中药治疗,具体成分也无法提供,因此不除外院外中药药物里含抗甲状腺药物成分,由此患者甲功变化急剧。

那该患者接下来该怎么治疗?

Graves病眼病的诊治流程



该患者目前EUGOGO评估标准属于中重度,属于活动性。根据2016年欧洲甲状腺学会/欧洲 Graves眼病专家组Graves眼病管理指南推荐的诊治流程,我们选择大剂量糖皮质激素冲击治疗控制病情,予以甲泼尼龙500mg一次,患者眼部不适较前改善,并建议出院后继续甲泼尼龙500mg每周一次,共六周,随后250mg每周一次,共六周(累积剂量4.5g)。

2016年欧洲甲状腺学会/欧洲 Graves眼病专家组Graves眼病管理指南建议,对于多数患者,静脉甲基强的松龙起始剂量500 mg,每周1次,持续6周,随后减至250 mg 每周1 次,持续6周,一个疗程共计12周,累积剂量 4.5 g。尽管,剂量的增加将更有利于临床活动度评分(CAS)及眼部症状的改善,但其不良反应的发生率也相应增加。因此,仅仅是针对病情严重的中重度活动性GO患者,甲基强的松龙推荐以 750 mg 起始,每周1次,持续6周,继以500 mg每周1次,持续6周(累积剂量7.5g)。

需注意的是,近期感染病毒性肝炎、肝功能明显异常、严重心血管并发症、未控制的高血压、精神异常及控制欠佳的糖尿病为激素冲击的禁忌证。治疗期间应每月监测肝酶、血糖及血压。推荐常规使用质子泵抑制剂预防消化道溃疡。此外,在治疗过程中应适当补钙,尤其是对存在多个骨质疏松危险因素的患者。

但对于该患者甲功的治疗,大家持有不同的想法,患者入院前4个月开始予以甲巯咪唑30mgqd,入院前甲功提示药物性甲减,入院后治疗方案调整为甲巯咪唑10mgqd,出院时复查甲功,提示促甲状腺激素水平较入院时高,经讨论,有专家认为甲巯咪唑减量即可,有专家认为甲巯咪唑减量同时用优甲乐,也有专家提议停用甲巯咪唑,用小剂量优甲乐。最终我们决定停用甲巯咪唑1周,并用优甲乐25ug每日一次,1周后复查甲功,嘱患者每周一次我科门诊随访。各位同行,你们有更好的建议吗?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797660, encodeId=aa1b1e9766028, content=<a href='/topic/show?id=35492325624' target=_blank style='color:#2F92EE;'>#主治医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23256, encryptionId=35492325624, topicName=主治医生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Dec 25 01:28:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039599, encodeId=f5af203959967, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 13 09:28:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373851, encodeId=9b833e3851da, content=mmi最好不要停, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4081474571, createdName=turkey310, createdTime=Sun Oct 13 13:50:09 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515316, encodeId=2cf7151531636, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540524, encodeId=2aca1540524c6, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797660, encodeId=aa1b1e9766028, content=<a href='/topic/show?id=35492325624' target=_blank style='color:#2F92EE;'>#主治医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23256, encryptionId=35492325624, topicName=主治医生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Dec 25 01:28:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039599, encodeId=f5af203959967, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 13 09:28:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373851, encodeId=9b833e3851da, content=mmi最好不要停, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4081474571, createdName=turkey310, createdTime=Sun Oct 13 13:50:09 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515316, encodeId=2cf7151531636, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540524, encodeId=2aca1540524c6, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=)]
    2019-11-13 xinmeili
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797660, encodeId=aa1b1e9766028, content=<a href='/topic/show?id=35492325624' target=_blank style='color:#2F92EE;'>#主治医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23256, encryptionId=35492325624, topicName=主治医生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Dec 25 01:28:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039599, encodeId=f5af203959967, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 13 09:28:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373851, encodeId=9b833e3851da, content=mmi最好不要停, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4081474571, createdName=turkey310, createdTime=Sun Oct 13 13:50:09 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515316, encodeId=2cf7151531636, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540524, encodeId=2aca1540524c6, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=)]
    2019-10-13 turkey310

    mmi最好不要停

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1797660, encodeId=aa1b1e9766028, content=<a href='/topic/show?id=35492325624' target=_blank style='color:#2F92EE;'>#主治医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23256, encryptionId=35492325624, topicName=主治医生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Dec 25 01:28:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039599, encodeId=f5af203959967, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 13 09:28:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373851, encodeId=9b833e3851da, content=mmi最好不要停, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4081474571, createdName=turkey310, createdTime=Sun Oct 13 13:50:09 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515316, encodeId=2cf7151531636, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540524, encodeId=2aca1540524c6, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797660, encodeId=aa1b1e9766028, content=<a href='/topic/show?id=35492325624' target=_blank style='color:#2F92EE;'>#主治医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23256, encryptionId=35492325624, topicName=主治医生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Dec 25 01:28:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039599, encodeId=f5af203959967, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 13 09:28:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373851, encodeId=9b833e3851da, content=mmi最好不要停, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4081474571, createdName=turkey310, createdTime=Sun Oct 13 13:50:09 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515316, encodeId=2cf7151531636, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540524, encodeId=2aca1540524c6, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Oct 11 11:28:00 CST 2019, time=2019-10-11, status=1, ipAttribution=)]
    2019-10-11 pps20023

相关资讯

Graves眼病4种治疗方案汇总,快收藏!

眼部损害是Graves病最常见的甲状腺外表现,又称Graves眼病(GO),是一种器官特异性自身免疫病。女性发病率约为0.016%,男性为0.003%。虽然发生率不是很高,但病情严重者可危及视力,需要积极处理。由于其发病机制目前尚不十分清楚,临床诊治较为困难。本文对目前的常用治疗方案进行总结。

Thyroid:自噬与Graves眼病的发生发展相关

关于Graves眼病(GO)的发病机制目前尚未完全清楚。比较可能的机制是眼肌周围的成纤维细胞(perimysial fibroblast)、眼球后脂肪组织的脂肪细胞和成纤维细胞的细胞膜上有促甲状腺激素受体(TSH-R)。T细胞作用于上述有TSH-R的细胞,分泌细胞因子,刺激这些细胞增生,分泌糖胺聚糖(glycosaminoglycan)和表达主要组织相容性复合物(MHC class Ⅱ)抗原(HL

Invest Ophthalmol Vis Sci:磷脂酰肌醇3-激酶特异性抑制剂Idelalisib对Graves眼病的脂肪生成具有抑制作用

韩国首尔延世大学医学院视觉研究所的Ko J和Kim JY近日在Invest Ophthalmol Vis Sci杂志上发表了一篇文章。新的研究表明,磷脂酰肌醇3-激酶(PI3K)-AKT途径参与Graves眼眶病变(GO),并在其发病机制中具有重要作用。这研究中,作者在体外GO眼眶成纤维细胞中使用选择性PI3K抑制剂idelalisib进行处理,研究其对脂肪合成的治疗效果。